Equillium announced that it plans to develop EQ001 for the treatment of lupus nephritis. Equillium remains on track to initiate the EQUATE Phase 1b/2 trial in acute graft-versus-host disease in the first quarter of 2019 and initiate a proof-of-concept trial in severe asthma in the second quarter of 2019. Equillium will host a conference call today to provide further details. “Our decision to explore EQ001 for the treatment of lupus nephritis is consistent with our goal of developing promising new therapies that help patients with severe and underserved autoimmune diseases,” said Daniel Bradbury, chairman and chief executive officer of Equillium. “With over 100,000 LN patients in the United States alone and no currently FDA-approved therapies, there is a strong clinical rationale for pursuing this indication. Additionally, we believe EQ001’s unique mechanism of modulating both the activity and trafficking of pathogenic T cells provides a strong scientific rationale and highly differentiated approach to treat this difficult disease.”
https://thefly.com/landingPageNews.php?id=2870821
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.